Method for reducing blood insulin levels by reducing in vivo cathepsin L activity
AssigneeNewMillennium Pharmaceutical, Inc.
InventorsHamilton H. Yong, Jingming Chen, Guo-ping Shi
Life of this patent
Estimating the term…
Abstract
Methods and compositions are provided for modulating blood insulin levels of animals by targeting the gene and gene products of cathepsins, particularly cathepsins L, K, and S, and especially cathepsin L. The method comprises: administering to the animal an agent that reduces an in vivo level of cathepsin L activity such that the blood insulin level of the animal is reduced. The method can be used to treat hyperinsulinmia and related diseases such as insulin resistance, type II diabetes, and hyperglycermia.
Claims22
A method for treating hyperinsulinmia by reducing a blood insulin level of an animal comprising:
- administering to the animal an agent which reduces an in vivo level of cathepsin L activity such that the blood insulin level of the animal is reduced.
Dependencies are inferred from the claim text.